FOR YOUR PATIENTS
Explaining the Envisia test to patients
The Envisia classifier is a genomic test that aids clinicians in differentiating between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD), without having to do a surgical lung biopsy.
How to explain Envisia to patients
The test analyzes lung tissue samples collected during a transbronchial biopsy (TBB), a nonsurgical procedure commonly used to diagnose lung diseases.
A doctor collects 3-5 lung tissue samples during a nonsurgical transbronchial biopsy (TBB) and sends them to the lab.
The test looks at 190 genes commonly associated with fibrosis or inflammation.
The results indicate either positive or negative for usual interstital pneumonia (UIP), which helps guide next steps.
This handout may help healthcare professionals discuss the Envisia classifier with patients and how the test works.
Billing and reimbursement
Covered by Medicare
The Envisia test is covered by Medicare. Veracyte bills Medicare and third-party payers directly.
The Veracyte Access Program provides financial support for both eligible uninsured and commercially available insured patients with financial need.